Breast Cancer Trials’ Post

Are you eligible for the BRCA-P clinical trial? Women with a BRCA1 gene mutation have a 70% risk of developing breast cancer over their lifetime. That's why the BRCA-P clinical trial has the potential to be a game-changer in breast cancer prevention. We are investigating if an injection of the drug denosumab, twice yearly for five years, is a safe and effective way of preventing breast cancer for women with a BRCA1 gene mutation. If you have a confirmed BRCA1 gene mutation, are aged between 25-55, have not received a breast cancer diagnosis, and have not completed surgery to remove both breasts, you could be eligible for this trial. Learn more about this very important research: https://lnkd.in/gdD_K_wE

Identification of a 24-gene panel and a novel marker of PODXL2 essential for the pathological diagnosis of early prostate cancer. Read the article here: https://lnkd.in/g4ggd4Gk

Carcinotech Ltd printed tumours serve as a versatile platform for high-throughput, precise, and swift in vitro screening of a wide range of drugs, including novel compounds, combinations, and repurposed therapies. Beyond mere screening, these bioengineered tumours offer invaluable insights into drug efficacy, pathway analysis, and cytotoxicity assessment. By mimicking the complexities of real tumours, they significantly de-risk pre-clinical trials, providing researchers with translational data crucial for understanding cancer heterogeneity and microenvironmental influences. Learn more in Genetic Engineering & Biotechnology News

Circulating tumor cells (CTCs), tumor-educated platelets (TEPs), cell-free nucleic acids released by tumor cells, such as circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and cell-free RNA (cfRNA), and exosomes are used as sources of liquid biopsies. Playing role in the pathogenesis of human malignancies, analysis of these sources can provide easier access to the genetic and transcriptomic information of the cancer tissue even better than the conventional tissue biopsy. This review article explains the principles and clinical potentials of liquid biopsy in the management of human malignancies with a special focus on colorectal cancer. https://lnkd.in/eQRFFNNt

Microsatellite instability (MSI) occurs due to a deficiency in mismatch repair (MMR) proteins, which are responsible for correcting errors in DNA when cells divide. This condition leads to the accumulation of mutations in microsatellite regions of the genome. MSI is frequently observed in certain types of cancer, including colorectal cancer (CRC). Tumors that occur as a result of MSI are more responsive to immunotherapies, making MSI testing a critical part of treating CRC. While MSI testing by PCR is the accepted gold standard, immunohistochemistry (IHC) is still commonly used to detect the presence or absence of MMR proteins. Yet, both methods offer fundamentally different information about a tumor sample. When used in parallel, MSI by PCR and IHC-MMR testing methods can increase the overall number of accurately characterized tumors to over 99%. Learn more about both methods and the benefits of co-testing: https://bit.ly/3THo4tF

New study!🍉 Regulatory role of lncH19 in RAC1 alternative splicing: implication for RAC1B expression in #colorectalcancer ------------------- Aberrant alternative splicing events play a critical role in cancer biology, contributing to tumor invasion, metastasis, epithelial-mesenchymal transition, and drug resistance. Recent studies have shown that alternative splicing is a key feature for transcriptomic variations in colorectal cancer, which ranks third among malignant tumors worldwide in both incidence and mortality. In this paper, alice conigliaro et al. found, that in colorectal cancer cells, the long non-coding RNA H19 can bind immature RNAs and splicing factors as hnRNPM and RBFOX2. Look here👇 https://lnkd.in/d_GYip5i #LongnoncodingRNA #Alternativesplicing #RNAbindingproteins IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

Additional MoA on NK in TME Toffoli et al. demonstrated that an off-the-shelf, clinical-stage allogeneic NK cell product (derived from ex vivo-expanded and -differentiated umbilical cord blood CD34+ hematopoietic stem cells) induced the differentiation of infiltrating monocytic cells to an activated DC-like phenotype, triggered tumor cell lysis, and controlled tumor growth efficiently in both primary and metastatic colorectal cancer single-cell suspensions. The combination of NK cells with a toll-like receptor 7/8 agonist (R848) activated CD8+ and CD4+ TlLs, reduced activated Tregs, and induced a pro-inflammatory (IFNγ, IL-2, IL-12p70, and IFNα) cytokine and chemokine release profile. (Contributed by Shishir Pant from ACIR) #NK, #DC, #CRC

Microsatellite instability (MSI) occurs due to a deficiency in mismatch repair (MMR) proteins, which are responsible for correcting errors in DNA when cells divide. This condition leads to the accumulation of mutations in microsatellite regions of the genome. MSI is frequently observed in certain types of cancer, including colorectal cancer (CRC). Tumors that occur as a result of MSI are more responsive to immunotherapies, making MSI testing a critical part of treating CRC. While MSI testing by PCR is the accepted gold standard, immunohistochemistry (IHC) is still commonly used to detect the presence or absence of MMR proteins. Yet, both methods offer fundamentally different information about a tumor sample. When used in parallel, MSI by PCR and IHC-MMR testing methods can increase the overall number of accurately characterized tumors to over 99%. Learn more about both methods and the benefits of co-testing: https://bit.ly/4ciF9Bz

📚 New #review sharing! Happy reading! Title: Clinical relevance of circulating tumor DNA in #OvarianCancer: current issues and future opportunities 📝 Authors: Elena Trevisi, Sessa Cristiana, Ilaria Colombo * The current knowledge and the potential clinical value of liquid biopsy in OC is discussed in this review to provide an overview of the clinical settings in which its use might support and improve diagnosis and treatment. 📢 This article belongs to the special issue "The Implementation of Liquid Biopsy in Clinical Practice for Different #SolidTumor", edited by Dr. Erika Martinelli and Dr. Giulia Martini, MD   🔎 Keywords: #LiquidBiopsy, ovarian cancer, circulating tumor DNA, cell-free DNA   🔗 Read online at https://lnkd.in/gdT7r8mg Download PDF at https://lnkd.in/gAxXrY5f

"If you are a scientist and you only know one thing about tumor metabolism, it’s likely the Warburg effect. But who was Otto Warburg, and how did his discoveries regarding the metabolism of tumors shape our current thinking about the metabolic needs of cancer cells?" https://lnkd.in/e5YyV5Qv And for a deeper insight into Warburg and his importance with regard to understanding the link between sugar and cancer we highly suggest reading the book "Ravenous: Otto Warburg, the Nazis, and the Search for the Cancer-Diet Connection" by the amazing Sam Apple.